Covid-19 News and Discussions


COVID activity is high, but Canada not 'remotely close' to worst days of the pandemic: experts​

The latest COVID surge is being driven by highly contagious Omicron offshoots, sub-variants from the JN.1 lineage that drove last winter's spike

Get the latest from Sharon Kirkey straight to your inboxSign Up
Author of the article:
Sharon Kirkey
Published Sep 05, 2024 • Last updated 1 hour ago • 6 minute read

214 Comments


A long line up of people.
People line up for the COVID-19 vaccinations in Toronto in April 2021. COVID is still killing Canadians, but at nowhere near peak pandemic levels. Photo by Ernest Doroszuk/Postmedia/File

Article content​

Nearly five years into its emergence in humans, wastewater data suggest SARS-CoV-2 activity is high across most of Canada, driven by variants that are significantly different from strains circulating even a year ago.



Weekly deaths, however, remain low overall — 54 deaths were reported nationally the week ending Aug. 24 — and nowhere near peak pandemic levels, according to the federal government’s most recent COVID epidemiology update. More than 900 deaths were reported in the third week of January 2022, the deadliest week on record, during the early Omicron surges.

Advertisement 2

Story continues below


“We’re not seeing waves of people ending up in hospital like we did earlier in the pandemic,” said Dr. Fahad Razak, an internist at St. Michael’s Hospital in Toronto.



“That’s a good thing. That should be celebrated. That reflects the broad immunity in the population,” Razak said.



Still, “in my hospital and hospitals across the province” people with COVID are ending up in hospital, though far fewer than before, infections can be unpredictable even in healthy people and long COVID remains an issue, Razak said. SARS-CoV-2 is also mutating, rapidly, to shake off immunity from previous vaccinations and infections and reinfect people.


Article content


“I don’t think the majority of scientists who were looking at this early in 2020 or at the end of 2019 expected that, four years later, we’d be dealing with unrelenting waves of variants, which are immune evasive,” Razak said.



“We haven’t seen a widely distributed virus in recent human history that has had this property.”



That pattern of rapid mutation is the norm, making it all the more important to get updated vaccines to the highest risk groups, he and others said. But it could be another month before Health Canada approves three reformulated vaccines — and there’s confusion over whether the old formulas will be available until then.

Advertisement 3

Story continues below

8477439461379461479

Article content


Ontario and several other provinces issued notices that Health Canada had ordered remaining supplies of last spring’s booster shots targeting the then-dominant XBB strain quarantined and destroyed effective Sept. 1 to make way for the new updated vaccines, creating a gap where no vaccine would be available.



“If you want a vaccine in September, forget about it,” University of Ottawa’s Amir Attaran said on X, formerly Twitter.



“It doesn’t make any sense to me — the obviously reasonable thing to do is get your new vaccine in hand, before withdrawing the old one,” Attaran, a professor in the faculty of law and School of Epidemiology, Public Health and Community Medicine, told National Post.



“You don’t strip yourself naked when your clothes are in the washing machine.”



The old vaccines are still modestly effective, he said. “Why destroy vaccines during a big COVID wave?”



In a statement to National Post, the Public Health Agency of Canada (PHAC) said withdrawing existing XBB vaccines “is part of regulatory and supply management best practices,” consistent with the approach to annual flu shots.

Posted

NP Posted
Get a dash of perspective along with the trending news of the day in a very readable format.

Sign Up
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Advertisement 4

Story continues below


Article content


A transition plan to move from the current supply to updated vaccines targeting current strains “provides each province and territory the flexibility to ensure ongoing access to current supply until new vaccines are approved,” the agency said. “This includes a period of transition to full removal.”



The government also maintains a federal reserve of XBB vaccines “for any unexpected public health need,” the statement said.



COVID outbreaks in long-term care and other congregate settings have been slowly increasing since June. Concentrations of virus detected in wastewater — sewage — indicates “high” levels of COVID activity in British Columbia, Manitoba, Ontario, Nova Scotia and Newfoundland and Labrador, and “moderate” activity in the Yukon, Quebec, Prince Edward island and New Brunswick, according to a federal wastewater monitoring dashboard that covers just 29 per cent of the population.



With schools reopened and flu and other seasonal respiratory viruses on the doorstep, “we’re trending towards a not-so-good place right now,” said Dr. Nitin Mohan, an assistant professor at Western University’s Schulich School of Medicine and Dentistry.

Advertisement 5

Story continues below


Article content


We clearly have no reliable ability to predict the evolutionary trajectory of the virus


The latest COVID surge is being driven by highly contagious Omicron offshoots, sub-variants from the JN.1 lineage that drove last winter’s spike.



Health Canada is reviewing Pfizer and Moderna’s formulations targeting KP.2, and Novavax’s against JN.1, although another sub-variant, KP.3.11 now accounts for more than half of sequences tested, and growing.



The only thing a virus “cares” about is its ability to spread, said Matthew Miller, Canada Research Chair in viral pandemics at McMaster University.



Today’s sub-variants, dubbed FLiRT for their mutations, have made a pair of mutations that help the virus dodge antibodies produced by previous infections and vaccinations and evade pre-existing immunity — mutations that on their own make the virus less able to stick to our cells and infect us.



To compensate, the variants have made mutations in a different part of the virus that make it better able to bind to and infect cells.



A remarkable mutation event like the emergence of Omicron, which had more than 50 known mutations compared to Alpha, Delta and earlier strains, is unlikely.

Advertisement 6

Story continues below


Article content


But almost every three to four months, the virus becomes different enough “that a large group of the population no longer has sufficient immunity to prevent infection,” Miller said.



It’s proving hard to keep up. “We clearly have no reliable ability to predict the evolutionary trajectory of the virus,” Miller said. “We just don’t have the models that tell us, ‘How is this virus going to change in three months so that we can make a vaccine that will reflect the new virus that doesn’t exist yet?'”



Even when mismatched, the vaccines tend to do an “exceptionally good job.” The protection from infection is relatively short-term, but protection against severe disease lasts longer. “Their ability to protect against severe infections, hospitalization and death remain stable over much longer periods.”



“I think we should expect the same thing from these upcoming vaccines,” Miller said.



Unlike influenza or respiratory syncytial virus, COVID is very much a year-round virus and tends to peak every three to six months, though “there really isn’t a time when the virus is non-existent,” Mohan said. “We’re still seeing deaths from SARS-CoV-2 in numbers that people from my world feel are significantly higher than they should be.”

Advertisement 7

Story continues below


Article content


Those most at risk of severe COVID include people over 65, people with heart disease, diabetes, cancer or other underlying medical conditions, people who take immunosuppressive drugs, pregnant women and children with complex medical needs.



Cold and flu-like symptoms continue to be the main symptoms, but there’s lots of variability, Miller said.



“We should respect that the viral evolution has been highly unpredictable,” said Razak, a Canada Research Chair at the University of Toronto.



“In a year or two years, maybe we’re presented with a different situation. But based on today’s variant, the pattern of illness, the pattern of severe illness, there is nothing to suggest that we’re anywhere close — remotely close — to what we experienced even a couple of years ago.”



Alberta saw 25 per cent fewer COVID-related deaths in the last season (which ended Aug. 24) compared to the previous season, the Edmonton Journal reported.



However, Quebec saw higher mortality rates during this summer’s COVID wave than last year’s, the Montreal Gazette reported.



“We should, in general, try to prevent infections where possible, and, for the highest risk people, we need to get (the newer) vaccine, ideally timed to prevent critical illness like hospitalization,” Razak said.

Advertisement 8

Story continues below


Article content


But COVID isn’t the only virus spreading. Many parts of the country are seeing higher rates of pertussis, or whooping cough, and while waiting for the updated vaccines there’s a “whole portfolio” of other strategies to reduce the spread of respiratory viruses in general, Razak said, including opening windows to improve ventilation, not exposing others when you’re sick and masks for high-risk people in high-risk settings.



Only about half of people in higher risk age groups were vaccinated with the updated XBB booster shots in the spring campaigns. “There’s an opportunity to protect people most at risk,” Razak said. “When the (new) vaccines become available, those vaccine rates should be higher than what we saw in the spring.”
 

Thursday's Pandemic Update: A Look At Some New US Covid Numbers​


 

UVA researchers look to treat Long Covid symptoms​


 

What’s Going Around: COVID, allergies, sore throats​


 

Covid Situation Report: Sep 5, 2024​

Update on Covid providing information on prevalence and hospital admissions for England and its regions. This post is best viewed using the browser or Substack app.​


BOB HAWKINS
SEP 05, 2024

11
3
2
Share

Introduction.

This report is part of a weekly series that summarises the Covid situation in England and its regions.
A reminder that not all of the data previously included in the situation update is now available on a weekly basis. Where relevant, changes to the content and data sources have been noted.
This week the data published for England covers only case rates from the UKHSA Covid dashboard. The latest available data for Scotland, Wales and Northern Ireland is provided together with the key points from the recent NHS statement on the Autumn 2024 Booster Vaccination. Finally, there is a short update on Covid deaths in England and Wales.

Summary.

Recent data for England, Scotland, Wales, and Northern Ireland show that Covid levels are now stabilising at relatively low levels indicating the end of the latest wave.
Over the past week, daily case rates in England have plateaued at low levels, signalling the summer wave is likely over. Although case rates are stable in most regions there are early signs of increases in some northern regions.
In Scotland, hospital admissions and the number of beds occupied by Covid patients have also stopped falling and have now plateaued at relatively low levels.
In Wales the Covid cases and hospital admissions levels have also stopped falling but are at relatively low levels.
Northern Ireland is experiencing a similar trend, with hospital admissions for community-acquired Covid falling from the latest peak although levels have plateaued over the past three weeks.
The NHS have reconfirmed the eligibility criteria for the Autumn 2024 booster campaign which will start on October 3, 2024.
Deaths due to Covid in England and Wales have continued to decline and have returned to levels below those seen at the same period lest year.
Although the data indicates that this recent wave is over, this is an important reminder that Covid is not presently a seasonal disease and may never become one. As such, we should anticipate potential future waves with the emergence of new variants, diminishing immunity levels, and increased mixing as we enter the autumn months.
As always, it’s important to remember that the risk of hospitalisation from Covid infection increases significantly with age and for those immunocompromised. Also Long Covid remains a risk for all as shown by the recent ONS report. Therefore, it is prudent to take appropriate measures such as self-isolating when experiencing Covid symptoms and enhancing ventilation or wearing masks whenever possible.

Status of main respiratory diseases in England.

The UKHSA National influenza and COVID-19 surveillance report has moved to a condensed summer report and is now released every two weeks. Consequently, there is no updated information on Covid test positivity or weekly hospital admissions available to report. The next update will be published on Thursday, Sep 12 2024.

Covid case rates in England​

The UKHSA Covid dashboard continues to publish daily case rates for England on a weekly basis. As the majority of testing now occurs in hospitals or under medical supervision, these rates should closely align with hospital admissions. However, a comparison of daily case rates and daily admissions shows that this is not the case.
Appendix 1 indicates that although Covid case rates typically reflect the pattern of hospital admissions, there is a notable discrepancy in the magnitude of changes, with admissions experiencing a more pronounced fluctuation than case rates. Therefore, while case rates are helpful in signalling the general trend of Covid within the population, they do not precisely represent the degree of change.
The first chart in this section shows daily case rate per 100,000 individuals.
The chart indicates that Covid case rates have peaked and fallen for the past seven weeks indicating that the ‘summer’ wave is over. Current case rates are now lowers than those observed during the peak in May. It is important to note, as detailed above and in Appendix 1, that comparisons with the peak in Winter 2023 are not recommended.
The next panel chart in this section shows Covid rates for the regions of England. Hover your cursor over one of the chart lines to display the admission rates for all regions.
The panel charts indicate that following the recent decline, daily case rates are now stabilising at relatively low levels across most regions. However, there are early signs of an increase in the North East and Yorkshire and Humberside regions.

Daily Covid hospital admissions and bed occupancy.​

This section gives a more detailed examination of the most recent daily Covid data for hospitals in England.
NHS England stopped the weekly publication of data used to create these dashboards from April 4, 2024 and have moved to a monthly publication schedule. The next update will be available on September 12, 2024 covering August data.

Scotland weekly hospital admissions and bed occupancy​

Scotland continues to publish weekly data on hospital admissions and bed occupancy for Covid as well as waste water monitoring data. The dashboard for Scotland’s data can be accessed here.
The following panel chart shows the most recent data for weekly Covid hospital admissions up to Aug 25, depicted in blue, together with the number of beds occupied by Covid patients up to Sep 1, shown in orange. The number of occupied beds represent patients being treated for Covid as well as those being treated with Covid.
The charts show that the recent summer Covid wave in Scotland led to more hospital admissions and a greater number of beds occupied by Covid patients compared to the 'winter' wave. Nevertheless, there has been a marked decrease in both admissions and bed occupancy since the peak in summer, even though the figures have stabilised in the latest week.
Wastewater data reporting is currently paused until the end of September as the responsibility for laboratory Covid water samples testing transfers from Scottish Environment Protection Agency (SEPA) to NHS Lothian.

Wales Covid cases and hospital admissions.​

Public Health Wales publishes a weekly Covid dashboard, presenting key Covid hospital indicators for the preceding 90 days. This dashboard can be found here. Additionally, data regarding Covid cases detected through testing in hospitals and other medical facilities are released every week.
The following charts shows the latest data for the weekly (7 day rolling sum) number of cases reported.
While the weekly cases have plateaued in the most recent week, there has been a notable decline over the past eight weeks indicating that the summer wave is over. This fall follows a surge in cases over the summer that surpassed the 'winter' wave, reaching the highest point in over a year.
The following chart gives the trend for weekly hospital admissions in Wales.
Hospital admissions for Covid increased in June, but have now fallen significantly for the past eight weeks, mirroring the trend observed in Covid cases, and confirming that the ‘summer’ wave is over.

Northern Ireland hospital admissions​

Public Health Northern Ireland publishes a weekly COVID-19 Epidemiological Bulletin that provides data on Covid cases, hospital admissions and occupancy and care home incidents. The full report, published every Thursday, can be found here.
The chart below presents the weekly count of Covid hospital admissions for cases where the infection was contracted in the community, thereby excluding patients who contracted Covid while in hospital. It is important to note that the hospital admissions data for other home nations include patients who contracted infections in the hospital, making them not directly comparable to the data from Northern Ireland.

The chart shows a similar pattern to that seen in Scotland Wales, with the 'summer' wave's peak nearly reaching the heights of the 'winter' wave. However, since then the number of admissions has fallen and has now stabilised at a relatively low level indicating that the summer wave over.

Autumn 2024 Booster Vaccination Campaign​

Last week, the NHS England published an update on the Autumn/Winter vaccination campaigns for Covid, Flu, and RSV respiratory viruses. The update confirms the dates when vaccinations will start as well as eligibility. The update can be found here.
The Autumn 2024 Covid booster campaign will start on October 3, 2024 and that most flu and COVID-19 vaccinations should be completed by December 20, 2024. The complete list of individuals eligible for the Autumn 2024 booster published by the UKHSA across all four nations of the UK are:
  • adults aged 65 years and over;
  • residents in a care home for older adults;
  • individuals aged 6 months to 64 years in a clinical risk group;
  • frontline NHS and social care workers: and
  • those working in care homes for older people.
The only difference from the Autumn 2023 booster campaign is that “persons aged 12 to 64 years who are household contacts of people with immunosuppression” are no longer eligible.
Eligible individuals will either be contacted directly by their General Practice or will be able to book on the national booking system from Monday September 23, 2024.

Covid Deaths in England and Wales​

The Office of National Statistics (ONS) publishes weekly reports on the number of deaths recorded on death certificates that are due to Covid or where Covid was involved. The data available is for both England and Wales. The following chart compares the number of deaths due to Covid in England and Wales by the week of registration for 2023-24 with the previous 12 months. The chart does not include deaths where Covid was identified as a contributing cause on the death certificate.
The chart indicates that deaths due to Covid in England and Wales have continued to fall from the recent summer peak and they are now lower than the figures reported for the same period a year ago.
Overall the weekly death toll due to Covid in 2023/24 has seen a substantial decrease from the previous year. In the 12 months leading up to Aug 23 , 2024, there were 6,818 deaths reported, compared to 13,006 deaths in the previous 12-month period — a 48% reduction.

In conclusion​

Although the amount of data currently being published has decreased, the limited information available for England suggests that although Covid levels are still higher than those seen in may they are now falling indicating an end to the ‘summer’ wave.
Data from Scotland, Wales, and Northern Ireland suggest that the recent 'summer' wave of Covid saw higher levels than the 'winter' wave. Nevertheless, the most recent figures indicate that this surge has probably ended.
Lastly, the UK Health Security Agency has released the eligibility details for the Autumn 2024 booster campaign, which largely follows the criteria of previous autumn campaigns.
As always, if you have any comments on this Covid Situation Report or suggestions for topics to cover, please post a message below.
Subscribed

Appendix 1. How reliable are Daily Covid Case Rates?

The UKHSA Covid dashboard continues to publish daily case rates for England on a weekly basis. As the majority of testing now occurs in hospitals or under medical supervision, these rates should be closely aligned with hospital admissions and the positivity rate of tests.
The first panel chart in this section tests that assumption by comparing the daily case rate per 100,000 individuals, shown in red, with daily hospital admissions for Covid reported by NHS England, depicted in blue.
The chart shows that while Covid case rates generally mirror the pattern of Covid hospital admissions, there is a significant disparity in the scale of changes. The grey shaded areas on each chart highlights the difference between the peak of the winter wave and the recent peak in June. Case rates experienced a 64% decrease, whereas hospital admissions saw a reduction of only 32% between the winter and June peaks.
In conclusion, although case rates are useful for indicating the overall trend of Covid in the population, they do not accurately reflect the extent of change. The likely reason for this is that testing levels have decreased by about a half since January.
 

B.C. posts highest COVID-19 hospitalizations since January in latest monthly update​

Hospital

ian-holliday-1-4645409.jpg

Ian Holliday
CTVNewsVancouver.ca Journalist
Published Sept. 5, 2024 9:16 p.m. EDT

The number of people hospitalized with COVID-19 in B.C. has risen to its highest level since January, according to the B.C. Centre for Disease Control's latest monthly update(opens in a new tab).

There were 214 test-positive COVID patients in provincial hospitals as of Thursday, according to the BCCDC. That's the second-highest total the agency has published all year, only slightly below the 219 seen on Jan. 4, the first – and still highest – total reported in 2024.


b-c--covid-19-hospitalizations-sept--5--2024-1-7027357-1725585215378.png
The number of people hospitalized with COVID-19 in B.C. in 2024, as reported by the B.C. Centre for Disease Control, is shown. (CTV News)

Thursday's update showed the number of lab-confirmed cases rose each week in August, with 365 new positive tests recorded during the week of Aug. 4 to 10 and 462 recorded last week.

The percentage of tests coming back positive has also risen since the start of last month, jumping from 15.8 per cent during the week that ended Aug. 10 to 18.7 per cent during the most recent epidemiological week, which ended Aug. 31.

That's the highest test positivity rate the province has recorded since October 2023.

The number of new infections reported by the BCCDC represents only a small fraction of the total spread of the SARS-CoV-2 virus in the province, because relatively few people qualify for lab-based testing and the province does not track the results of at-home rapid tests.

Wastewater surveillance data in the province shows viral concentrations "have remained elevated" since the start of last month, according to the BCCDC.

The independent organization COVID-19 Resources Canada estimated in its most recent forecast(opens in a new tab) that roughly one in 27 B.C. residents is infected, with between 196,900 and 224,800 new infections expected this week.

The organization rates the B.C.'s current COVID risk as "severe."
 

No Novavax COVID-19 vaccine in Canada this fall, immunocompromised N.B. woman feels 'expendable'​

Linda Wilhelm wants protein-based vaccine, cites rheumatoid arthritis flare-ups after mRNA vaccines​


Bobbi-Jean MacKinnon · CBC News · Posted: Sep 06, 2024 5:00 AM EDT | Last Updated: 2 hours ago
A woman with short hair and glasses, sitting in a living room, holding up her hands, twisted by rheumatoid arthritis.

Linda Wilhelm says she's had longer and worse flare-ups of her rheumatoid arthritis after each mRNA COVID-19 vaccine she has received. (Google Meet/CBC)

Social Sharing​

  • Facebook
  • X
  • Email
  • Reddit
  • LinkedIn

comments
Linda Wilhelm, 64, of Bloomfield, N.B., is planning a road trip to the United States. But it's not to go sightseeing or shopping.

Wilhelm, who suffers from severe rheumatoid arthritis, hopes to get the updated Novavax COVID-19 vaccine, which won't be available in Canada as part of the fall vaccination campaign, unless provinces and territories order doses on their own.

Wilhelm, president of the Canadian Arthritis Patient Alliance and a member of the Canadian Immunocompromised Advocacy Network, says the protein-based vaccine is a better option for immunocompromised people like her than the more common Pfizer-BioNTech and Moderna mRNA vaccines. She says she feels "expendable" and urges the federal government to reconsider.

Less than two months ago, the network wrote to numerous federal, provincial and territorial officials, calling for improved access to Novavax and increased awareness.

They contend many immunocompromised people have suffered adverse reactions following immunization with mRNA vaccines, but have responded well to Novavax, which is included in the National Advisory Committee on Immunization's fall guidance for people 12 and older.

Disease flare-ups after mRNA shots​

Wilhelm says she has received six mRNA vaccines, both Pfizer and Moderna, and experienced longer and worse flare-ups of her rheumatoid arthritis with each one.

"You're tired and you're sore and you feel like you have the flu all the time," said Wilhelm, who was diagnosed at age 23.

WATCH | 'I'm going to be going on a road trip, I guess':

default.jpg

Covid vaccines are coming this fall, says Health Canada. But not Novavax​


2 hours ago
Duration2:10
Linda Wilhelm of Bloomfield, near Sussex, considers the protein-based shot a better option for her and others who are immunocompromised. But she says she may have to cross the border to get it.
When her third shot prompted a three-month flare, she started to think, "This is not real good," because the disease that ravaged her body for decades and resulted in 14 joint replacements or fusions, including both knees, both hips and both shoulders, had been stable for about 20 years. Prior to that, she was largely bed-bound and required a wheelchair.

But the married mother of three and grandmother of six was "terrified" of getting COVID, so she kept getting mRNA shots, with her latest flare lasting more than eight months and affecting her left elbow — one of only two healthy joints she had left.

In addition, her hands, while badly gnarled by the disease, never used to hurt. After the boosters, however, she suffered a "gnawing, uncomfortable, horrible pain" that kept her awake at night.

No adverse reaction to Novavax​

Wilhelm heard through a friend that immunocompromised people who received the Novavax vaccine had fewer adverse reactions. But she contracted COVID in October 2023 before she found a pharmacy that carried it.

She was "very ill" for two months, and in her weakened state ended up getting RSV, respiratory syncytial virus, for about another two months, but recovered.

A woman wearing sunglasses, standing on a sandy beach as waves roll in.

Wilhelm describes the two months she spent battling COVID-19 as 'awful,' but she managed to get through it. She says she's terrified of getting COVID again, but considers the risk of another rheumatoid arthritis flare-up after an mRNA vaccine even worse. (Submitted by Linda Wilhelm)
In March, Wilhelm began her search for Novavax again. After being referred back and forth between pharmacies and the Department of Health, she received a dose in mid-April in Saint John — about 45 minutes from her home, with no adverse reaction.

She wants to stick with Novavax, but that won't be an option here, Health Canada confirmed to CBC News.

Up to 19M mRNA vaccine doses coming​

Canada will be receiving up to 19 million doses of mRNA vaccines, pending regulatory authorization, said spokesperson Nicholas Janveau.

Health Canada is currently reviewing vaccines from Pfizer and Moderna that target the KP.2 strain, he said. The latest strains of Omicron circulating in Canada and the U.S. have names that start with KP.

Health Canada is also reviewing a vaccine from Novavax that targets the earlier JN.1 strain. "However, Canada's current contract with Novavax only provides access to domestically manufactured vaccines, which Novavax has been unable to confirm for the 2024/25 season," Janveau said.

A health-care worker wearing a medical mask draws COVID-19 vaccine from a vial into a needle.

Health Canada expects to finish reviewing updated COVID vaccines by 'early autumn,' on the heels of the U.S. approving two updated vaccines to protect against hospitalizations and deaths. (Edwin Hunter/CBC)
If Novavax's JN.1 vaccine does get approved, provinces and territories "may choose to procure independently from Novavax from supply produced in India for their fall vaccination campaigns," he added.

But "New Brunswick and other provinces have investigated and are unable to find other options to procure this vaccine," according to Department of Health spokesperson Sean Hatchard.

"The amount of vaccine that needed to be ordered to procure it independently was too large based on the minimal demand in the province," he said.

'Very low' demand for Novavax​

Demand for Novavax has been "very low" across the country, according to the Health Canada spokesperson. Of the 125,000 Nuvaxovid XBB.1.5 vaccines ordered in 2023, only 5,529 doses have been administered, as of June 30, 2024, he said.

Wilhelm contends uptake has been low because many people either don't know about the protein-based vaccine, or have had a hard time trying to get it.

Four vials with the Nuvaxovid COVID-19 vaccine from Novavax

Wilehlm says she had no adverse reaction to the protein-based Novavax COVID-19 vaccine in April and contends it's a better option for immunocompromised people like her. (Frank Simon/Reuters)
About 14 per cent of Canadians aged 15 or older have a compromised immune system, as of 2020, according to Statistics Canada. That's a "significant portion" of the population, Wilhelm said.

Immunocompromised people can use either type of vaccine, said Janveau. "Canada's National Advisory Committee on Immunization (NACI) no longer preferentially recommends one vaccine type over another."

Adverse reaction stats by vaccine type​

Wilhelm suspects mRNA vaccine reactions in immunocompromised people and others are underreported, due in part to the "abysmal" reporting system that does not include an online option.

In addition, many people may not think to file a report, she said, noting that even she, as an advocate, failed to report her reactions until recently.



Cost of vaccine in U.S. not covered​

Wilhelm says she's trying her best to stay healthy and not cost the health-care system money. "But [if] the government doesn't give me the tools I need to do that, then what do I do?"

Her only option, she said, is to drive to Maine — either three hours return to Calais, or six hours return to Bangor, depending on availability.



Wilhelm expects it will cost her about $180 US, or $243 Cdn, which the province won't cover, but says it's a small price to pay compared to the risk of another long flare-up, or getting COVID.

Still, she hopes the government will reverse its decision.
 

How testing has kept up with new COVID-19 variants​


 

Is COVID going around again? Most recent COVID variant, measles cases and listeria outbreak 2024​


 

Latest COVID-19 vaccines no longer free for uninsured​


 

Friday's Pandemic Update: Tons Of New Covid Data And News Just In​


 

COVID Summer Surge Now Driven by New Variant KP.3.1.1​


 

University of Alberta researchers retract COVID study, citing multiple errors​

Incidence of pediatric long COVID higher than had been reported in JAMA Pediatrics​

Dennis Kovtun · CBC News · Posted: Sep 06, 2024 3:17 PM EDT | Last Updated: 5 hours ago
A swing set in a playground on a summer evening.

The authors of the article, published in JAMA Pediatrics, requested a retraction because they identified "methodological (analytical) errors" in their original report. (Ahmar Khan/CBC)

Social Sharing​

  • Facebook
  • X
  • Email
  • Reddit
  • LinkedIn
A University of Alberta study on long COVID in children has been retracted.

The study found a "strikingly low" incidence of long COVID among children ages eight to 13 who contracted COVID-19.

However, during a review of their results, the authors discovered a key figure was incorrect.

The researchers had focused on a group of 271 children who tested positive for COVID and for whom there was sufficient data to determine the presence of long COVID.

Of that group of kids, only one — or 0.4 per cent — met the World Health Organization's definition of the condition, according to the study.

But after review, the authors found the actual incidence of long COVID in children and teens in the study group, is 1.4 per cent — or four out of 286 rather than one out of 271.

The authors of the article, published in JAMA Pediatrics, requested a retraction because they identified "methodological (analytical) errors" in their original report.

Dr. Piush Mandhane, a professor with the department of pediatrics at the University of Alberta, wrote a retraction note on behalf of his co-authors.

In the note, Mandhane explained that the errors impacted the researchers' estimate of prevalence of long COVID in children and adolescents and the "reported associations between pre- and post-COVID-19 symptoms."

"We identified a coding error whereby children with missing symptoms data were coded as having no symptoms. This error resulted in two participants being misclassified as having symptom resolution when they should have been classified as having [long COVID]," Mandhane wrote in the retraction note.

After the original study was published, the authors classified another child as having long COVID.

Other errors included the exclusion of 15 participants who should have been included in the study, and counting participants who fell outside the sample's age range of eight to 13 years old.

"We identified participants with COVID-19 [cases] who were recruited between one and 7.49 years and 14.5 and 19 years of age," Mandhane wrote in the retraction note.

There were other coding errors.

"We apologize to the readers and editors of JAMA Pediatrics for these errors," Mandhane wrote in the note.

"In discussion with the editors, who shared their concerns about the analyses and data reported, we are requesting a retraction of our research letter. All the authors of our research letter are in agreement with this retraction," Mandhane wrote.

JAMA Pediatrics is part of the JAMA Network, a group of medical scientific journals owned and published by the American Medical Association.

JAMA Pediatrics claims its impact factor is 24.7, which makes it the highest ranking pediatrics journal in the world.

JAMA Network declined to provide comment for this story.

"We believe the retraction letter from Dr. Mandhane speaks for itself," a public information officer for JAMA said in an email.

Dr. Kieran Quinn, a clinician-scientist at the Sinai Health System in Toronto, said in an interview that "it's important to acknowledge that research is a very difficult and sometimes messy endeavour."

"I commend the authors on their thoroughness in identifying these errors in their analysis and in transparently fixing them," Quinn said.

"In this case, they felt, along with the editors of the journal, that the errors were sufficient and numerous enough that they should actually retract the article rather than just correct it and update the analysis, which isn't always the case.

"I think that's actually an acknowledgement that they are good researchers and they're doing this in an ethical and responsible approach."
 

Users who are viewing this thread

Back
Top